Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
GDUFA And BsUFA Fees Set To Leap
US FDA Corrects Errors, Limits PDUFA Application Fee Increase
Aug 02 2024
•
By
Derrick Gingery
The FDA did not account for fee refunds and waivers in its FY 2023 and FY 2024 FAE calculations • Source: Shutterstock
More from Generics
More from Products